Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
A primary anorectal melanoma was reported in a 41-year-old man, presenting with rectal bleeding and polypoid tumor. Histopathology revealed a melanoma, but initial dissemination studies were negative. Unfortunately, metastases developed two years later, leading to the patient's death.
Scientists at Yale University propose a new explanation for cancer metastasis, suggesting that the fusion of a cancer cell with a white blood cell is the key to its spread. This theory has been validated in mouse studies and could lead to new therapeutic approaches.
A new study of 145 triple-negative breast cancers found that moderate or low-grade lesions were present in 23% of cases, with only a small percentage showing lymph node metastasis. The findings suggest that triple-negative breast cancers are a heterogeneous group and may not always be associated with cancer spread.
A new study demonstrates the effectiveness of multipolar radiofrequency ablation in treating patients with liver cancer, achieving complete tumor destruction in 66 out of 67 cases. After four years, 52% of patients are now tumor-free and 78% are still living.
A recent study found that USFNA of axillary lymph nodes in patients with newly diagnosed breast cancer improves diagnostic accuracy while minimizing negative results. The procedure, which measures cortical thickness, is safe and minimally invasive.
Researchers created a novel cell line that replicates the full spectrum of systemic metastatic cancer, enabling new discoveries about the role of macrophages in cancer's spread. The model has been shown to produce tumors in 100% of mice with healthy immune systems, paving the way for new therapies targeting these cells.
A study led by Memorial Sloan-Kettering Cancer Center researchers reveals that breast cancer cells use a signaling molecule called TGF-a to enhance their ability to spread to the lungs. This finding has significant implications for developing therapies to prevent metastasis in cancer patients.
Researchers discovered that SATB1 protein promotes tumor growth and metastasis in breast cancer. High levels of SATB1 expression are associated with poor prognosis, and reducing SATB1 can prevent the formation of invasive cells.
A combination of two platelet inhibitors, aspirin and APT102, reduced bone tumors in laboratory mice with breast or melanoma cancer. The drugs work by blocking platelets' ability to clot and aid tumor cells, slowing down metastasis.
A study led by Mary J. C. Hendrix found that the Lefty protein, secreted only in human embryonic stem cells, inhibits growth and spread of melanoma and breast cancer cells. This breakthrough suggests potential therapeutic modalities for cancer treatment and highlights the utility of isolating factors within the embryonic microenvironment.
Patients with HER2-positive tumours who receive trastuzumab treatment after diagnosing brain metastases have improved survival rates. The study found a correlation between triple receptor status and the incidence of brain metastases, as well as survival time.
Researchers at Duke University have developed a new method to model the genetic pathways underlying cancer, identifying connections between gene sets. The study reveals that specific gene sets work together to support cancer development and progression.
Two microRNAs, miR-373 and miR-520c, have been identified as promoting the spread of tumor cells. The study found that miR-373 is a potential biomarker for metastatic breast cancer and may be used to develop new treatments.
Researchers found that higher lymphatic vessel density and angiogenic microvessel density were associated with increased risk of metastasis in colorectal carcinoma. These findings suggest that LVD and MVD could be independent prognostic factors for disease-free survival.
Researchers identified three microRNA molecules that suppress the spread of breast cancer. Restoring these molecules reduces the ability of cancer cells to proliferate and migrate. The study adds to the growing list of cellular targets for drugs designed to prevent breast cancer metastasis.
A study by Memorial Sloan-Kettering Cancer Center identifies a group of microRNA molecules that control genes causing breast cancer metastasis. The loss of these microRNAs allows cancer cells to migrate and grow more rapidly, leading to increased risk of lung and bone metastasis.
Researchers found that a short course of hormonal therapy before and with radiation therapy slowed cancer growth by up to eight years, particularly the development of bone metastases. This delayed cancer progression increased survival rates among older men with potentially aggressive prostate cancer.
The study showed significant benefits of Avastin with Taxol in treating metastatic breast cancer, nearly doubling the time between chemotherapy initiation and tumor progression. This achievement demonstrates Avastin's potential as an antiangiogenic agent in breast cancer therapy.
Two studies from Mayo Clinic found that ER/PR negative breast cancers have the worst overall outcomes when spreading to the brain, resulting in shorter median survival times. Women with triple negative tumors and HER2+ tumors without estrogen or progesterone receptors have poor outcomes due to aggressive brain metastasis.
A combination of lapatinib and capecitabine significantly shrinks brain metastases in patients with aggressive HER2-positive breast cancer, with 10 patients experiencing a 50% reduction. The study's findings offer new hope for treatment options for women with advanced breast cancer who develop brain metastases.
Researchers have identified immunomodulatory anticancer drugs lenalidomide and pomalidomide as effective therapies for inducing fetal hemoglobin production in sickle-cell disease patients. Additionally, a new compound has been discovered to treat protein-losing enteropathy, a condition causing excessive protein loss from the gut.
Researchers found that VEGF-C gene therapy induced robust growth of lymphatic capillaries in mice, leading to functional collecting lymphatic vessels and improved lymph node transplantation outcomes. The treatment also showed promise in preventing systemic dissemination of metastases and improving patient safety.
A study published in CANCER found that non-white women with metastatic breast cancer experience poorer pain control, with a higher risk of severe pain. The researchers also found that inactive performance status and previous radiation treatment were associated with greater pain.
Researchers used FDG PET/CT to monitor early responses and found that combining EGFR-specific antibodies with VEGF-specific antibodies may improve anti-tumor efficacy. The novel approach also shows potential for anticancer therapy by monitoring molecular treatment responses.
Researchers at Ohio State University have found that stress hormone norepinephrine promotes tumor cell growth and metastasis in certain types of blood cancer. The study suggests that blocking norepinephrine receptors may slow disease progression and improve treatment outcomes.
Researchers have identified a molecule, osteopontin-c, that appears more accurate than existing biomarkers in predicting which breast cancers will develop into advanced forms. The discovery could one day influence therapy decisions and prevent patients from undergoing aggressive treatments.
Researchers present emerging therapies targeting cancer cells, including a small molecule inhibitor of protein kinase D and an oncolytic herpes virus that selectively targets cancer cells without damaging nerves. These treatments offer promising methods for controlling disease and improving patient outcomes.
The spleen's unique anatomical and immunological characteristics may explain why isolated splenic metastasis from colorectal carcinoma is rare. Experimental studies have shown that cancer cells injected into the spleen grow more slowly than those in other organs.
Researchers from UC San Diego have developed a more accurate method for predicting breast cancer metastasis by analyzing protein interactions. Their approach, which uses a network of genes rather than individual genes, improves metastasis prediction accuracy to around 72%.
A retrospective study of 68 postoperative CRC patients found that 18F-DG PET/CT detected more lesions than CT or ultrasonography alone in 30.4% of cases with recurrence and/or metastasis. The imaging technique also helped alter treatment plans in 16.2% of cases.
Researchers found significant IL-8 up-regulation in all inflammatory, non-malignant, and malignant colorectal entities compared to normal tissues. The study suggests an association between IL-8 expression and the development of colorectal cancer and liver metastases.
A recent study shows that overabundance of a single microRNA, microRNA-10b, can cause tumors to spread to distant tissues in mice. Researchers found that this microRNA disrupts the normal migration process of cancer cells by targeting the HoxD10 gene.
The Phase II EPOC study found that ZD4054, an endothelin A receptor antagonist, showed no difference in progression-free survival but reported encouraging overall survival data. The compound may have potential to increase median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC.
The Phase II study found a 45% reduction in risk of death and improved median overall survival of 24.5 months for patients treated with ZD4054 10mg once-daily compared to placebo.
Researchers identified a distinct subpopulation of cancer stem cells responsible for metastasis in human pancreatic cancer. The study found that CSCs expressing CD133 and CXCR4 play a critical role in tumor metastasis, and inhibiting these cells or transplanting non-metastatic cells can abolish metastatic tumor development.
Researchers have identified a protein on the surface of platelets that plays a key role in cancer-induced platelet aggregation, allowing cancer cells to evade the immune system and spread throughout the body. By blocking the interaction between podoplanin and CLEC-2, it may be possible to prevent tumor metastasis.
Researchers discover that the L1-CAM gene is highly expressed in colorectal cancer cells that have spread to the liver, while normal colon tissue lacks this gene. This finding highlights the importance of L1-CAM in metastasis and opens new avenues for cancer research.
Researchers identify specific H. pylori strains associated with precancerous gastric lesions, potentially underestimating the risk of gastric cancer. Meanwhile, a gene called OGR1 is found to suppress prostate cancer metastasis in mice, suggesting its potential as a novel metastasis suppressor gene.
Researchers identified a key protein that blocks structural support, allowing cancer cells to migrate and metastasize. The discovery may lead to the development of anti-cancer drugs targeting this mechanism.
A new study published in CANCER found that newer drug therapies, particularly aromatase inhibitors, have improved the survival of women with metastatic breast cancer. Survival rates increased by approximately 30% as these drugs became more widely used between 1991 and 2001.
The incidence of early stage metastatic breast cancers is increasing, attributed to changes in clinical practice. Sentinel lymph node biopsies often detect small numbers of tumor cells that do not necessarily indicate cancer spread.
Researchers at EPFL discovered how tumor cells exploit slow fluid flow in the lymphatic system to migrate to functional vessels. The study highlights the importance of biophysical environment and continuous slow flow in tumor cell migration.
Researchers suggest targeting beta1-integrin to treat cancer by reducing tumour cell proliferation and inducing cellular senescence, potentially preventing metastases. Blocking this protein function in transgenic mice with pancreatic insulinomas resulted in tumour cells becoming senescent and unable to form new tumours.
Researchers found mutations in integrin alpha 7 associated with cancer progression and metastasis in various cancer cell lines. Increasing normal integrin alpha 7 levels inhibited tumor growth and migration, indicating its potent tumor suppressor activity.
Researchers found that percutaneous ethanol injection (PEI) significantly reduces tumor volume and alleviates symptoms in patients with radioiodine-ineffective bone metastasis from thyroid cancer. PEI's effectiveness was also linked to improved quality of life for selected patients.
The drug lapatinib has modest but real activity against brain metastases, shrinking tumors and slowing disease progression in some breast cancer patients. The study's findings suggest that the drug should undergo further testing as a treatment for breast cancer with brain metastases.
Pazopanib, an oral angiogenesis inhibitor, demonstrated a 27% week 12 response rate and 73% total disease control rate in patients with advanced renal cell carcinoma. The study showed clear clinical activity in treating this type of cancer.
Pazopanib demonstrated high response rates of 27% and stable disease in 46% of patients with advanced renal cell carcinoma (RCC). In ovarian cancer, pazopanib showed biological activity in 41% of evaluable patients. These findings support further investigations into pazopanib's therapeutic potential.
A recent Phase II study evaluating the addition of GEMZAR to standard chemotherapy regimens showed promising results in treating stage II-III breast cancer. The treatment regimen demonstrated a high pathologic complete response rate, with additional benefits for HER-2 positive patients who received trastuzumab. These findings support t...
Alcohol drinking has been associated with a reduced risk of renal cell cancer. Childhood leukemia and lymphoma survivors face an elevated risk of secondary cancers, while treatment with clodronate did not improve survival for men with localized prostate cancer.
Researchers at UCSD School of Medicine targeted heparan sulfate in tumor blood vessels to inhibit angiogenesis and tumor growth. Modifying the action of this sugar uniquely impacted the tumor vasculature, altering its growth rate in lung carcinoma cells in mice.
Biologists at Memorial Sloan-Kettering Cancer Center identified a set of genes working together to remodel blood vessels and promote breast cancer spread to the lungs. Targeting these genes with drug combinations may prove useful in treating metastatic breast cancer.
Researchers at Vanderbilt University Medical Center have linked treatment-induced TGF-beta levels to increased circulating cancer cells and tumor metastases in a mouse model of breast cancer. Blocking TGF-beta may be clinically useful in combination with primary therapies.
The European Association of Urology (EAU) has recommended Sutent as a first-line treatment for patients with metastatic renal cell carcinoma. Clinical trials have shown that Sutent improves progression-free survival by more than doubling the median PFS compared to interferon-alpha. The new guidelines also highlight Sutent's higher obje...
A UBC discovery reveals a protein that changes tumour cells' shape and adhesive quality, allowing them to grow and spread. Researchers aim to develop targeted, non-toxic treatments using 'smart' molecules to block its function.
Research at UCSD School of Medicine suggests inflammation associated with tumor growth plays a key role in prostate cancer metastasis. A signaling pathway triggered by RANK ligand increases metastases in mouse models.
Researchers found that Gab-2 is essential for breast cancer metastasis but not initial tumor growth. The study suggests a novel mechanism for breast cancer metastasis and identifies Gab-2 as a possible new target for therapies.
A new screening protocol has been identified that can detect Lynch syndrome, a disorder that increases the risk of developing colorectal cancer at a young age. The screening procedure detected mutations in 69 patients and identified at least 57 HNPCC patients who would not have been screened under current testing practices.
Neural stem cells can be engineered to deliver anti-cancer drugs to metastatic cancer cells, potentially treating disseminated cancer. Researchers successfully eradicated metastases in a mouse model of neuroblastoma using this approach.
Researchers at City of Hope and St. Jude Children's Research Hospital developed a modified neural stem cell therapy that activates chemotherapeutic drugs primarily at tumor sites, sparing normal tissue. The approach showed promise in treating solid tumors, including neuroblastoma, with improved survival rates.